Edap Tms SA
NASDAQ:EDAP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.36
8.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Edap Tms SA
Edap Tms SA
Cash from Financing Activities
Edap Tms SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cash from Financing Activities
€20.3m
|
CAGR 3-Years
85%
|
CAGR 5-Years
60%
|
CAGR 10-Years
26%
|
|
|
Biomerieux SA
PAR:BIM
|
Cash from Financing Activities
-€131.5m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Carmat SA
PAR:ALCAR
|
Cash from Financing Activities
€40.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Biosynex SA
PAR:ALBIO
|
Cash from Financing Activities
-€12.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Cash from Financing Activities
€1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-5%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cash from Financing Activities
€2.5m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Edap Tms SA
Glance View
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.
See Also
What is Edap Tms SA's Cash from Financing Activities?
Cash from Financing Activities
20.3m
EUR
Based on the financial report for Dec 31, 2023, Edap Tms SA's Cash from Financing Activities amounts to 20.3m EUR.
What is Edap Tms SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
26%
Over the last year, the Cash from Financing Activities growth was 0%. The average annual Cash from Financing Activities growth rates for Edap Tms SA have been 85% over the past three years , 60% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
